Metreleptin: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), G-BA (Germany) and HAS (France), among others, recommended or restricted metreleptin, while NYE METODER (Norway) and ZIN (Netherlands) did not recommend it.
Assessment has run over 7.8 years, from 10 Aug 2018 at AWMSG (Wales) to 17 Jun 2026 at CIPM (Spain).
CIPM (Spain) changed its position: not recommended on 10 Jun 2021, recommended by 17 Jun 2026, after a resubmission.
No assessment is on file from PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 4 of 14 records date from 2023 or later.
AWMSG (Wales) was first to assess metreleptin, on 10 Aug 2018; TLV (Sweden) did not open a file until 24 Feb 2026 — a wide spread of 7.5 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 7 years in total.
Restriction is doing real work here: 3 of 11 decisive outcomes narrowed metreleptin to a subgroup rather than accepting or refusing it outright, at AIFA (Italy), G-BA (Germany) and TLV (Sweden).
4 of the 9 agencies here assessed metreleptin more than once, CIPM (Spain) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for metreleptin.
The full ledger for metreleptin reads 4 recommended, 4 not recommended, 3 restricted and 1 other, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| TLV (Sweden) | 24 Feb 2026 | Myalepta ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| SMC (Scotland) | 12 Jun 2023 | As an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients with: confirmed congenital generalised LD (B… | unknown | source |
| NYE METODER (Norway) | 22 Jan 2023 | Tillegg til kosthold som erstatningsterapi for å beh. komplikasjoner ved leptinmangel hos pasienter med lipodystrofi (LD… | not introduced | source |
| ZIN (Netherlands) | 8 Jul 2022 | GVS-advies herbeoordeling metreleptine (Myalepta®) bij de behandeling van gegeneraliseerde lipodystrofie | advice published (GVS) | source |
| CIPM (Spain) | 25 Nov 2021 | Indicación terapéutica: Myalepta está indicado, junto con la dieta, como tratamiento restitutivo para tratar las complic… | not financed by the SNS (financed 2026-06) | source |
9 further decisions for metreleptin, across 6 agencies, are not shown here. They include the most recent record on file, 17 Jun 2026 from CIPM (Spain); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- teduglutide — same ATC class A16A — Other alimentary tract and metabolism
- sapropterin — same ATC class A16A — Other alimentary tract and metabolism
- miglustat — same ATC class A16A — Other alimentary tract and metabolism
- migalastat — same ATC class A16A — Other alimentary tract and metabolism
- cerliponase alfa — same ATC class A16A — Other alimentary tract and metabolism
- givosiran — same ATC class A16A — Other alimentary tract and metabolism
Coverage: 14 decisions for metreleptin from 9 agencies, 2018 to 2026. Data to 7 Sep 2026. ATC class A16A — Other alimentary tract and metabolism. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.